Updated:
Sage Therapeutics, Inc.
Sage Therapeutics, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001597553, and its reported industry...
Overview
Sage Therapeutics, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001597553, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2025-02-11, it reported annual revenue of USD 41,243,000; net income of USD -400,666,000; total assets of USD 547,222,000 for the fiscal period ended 2024-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.
Company overview
- Legal name
- Sage Therapeutics, Inc.
- Classification
- Company
- Industry (SIC)
- 2834 — Pharmaceutical Preparations
- Headquarters
- Cambridge, MA, United States
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 0001597553
Financials
Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.
| Fiscal year | Period end | Revenue | Net income | Total assets | Cash and equivalents | Operating cash flow |
|---|---|---|---|---|---|---|
| FY2024USD | $41.2M | -$400.7M | $547.2M | $81.0M | -$267.2M | |
| FY2023USD | $86.5M | -$541.5M | $882.3M | $71.0M | -$540.6M | |
| FY2022USD | $7.7M | -$532.8M | $1.4B | $162.7M | -$460.0M | |
| FY2021USD | $6.3M | -$457.9M | $1.8B | $294.2M | -$378.2M |
Recent SEC filings
| Form | Filed | Period | Filing |
|---|---|---|---|
| 8-K | 8-K | ||
| 10-Q | 10-Q | ||
| 8-K | 8-K | ||
| 8-K | 8-K | ||
| 8-K | 8-K | ||
| 10-Q | 10-Q | ||
| 8-K | 8-K | ||
| DEF 14A | DEF 14A | ||
| 8-K | 8-K | ||
| 10-K | 10-K | ||
| 8-K | 8-K | ||
| 8-K | 8-K |
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Research Sage Therapeutics, Inc. in Altss
Track this company’s investors, transactions and relationships in Altss.